[go: up one dir, main page]

AR069746A1 - Conjugados de anticuerpos anti- rg-1 - Google Patents

Conjugados de anticuerpos anti- rg-1

Info

Publication number
AR069746A1
AR069746A1 ARP080105135A ARP080105135A AR069746A1 AR 069746 A1 AR069746 A1 AR 069746A1 AR P080105135 A ARP080105135 A AR P080105135A AR P080105135 A ARP080105135 A AR P080105135A AR 069746 A1 AR069746 A1 AR 069746A1
Authority
AR
Argentina
Prior art keywords
antibody
human
conjugate
associated molecule
binds
Prior art date
Application number
ARP080105135A
Other languages
English (en)
Original Assignee
Medarex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40427118&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR069746(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medarex Inc filed Critical Medarex Inc
Publication of AR069746A1 publication Critical patent/AR069746A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Anticuerpos anti-RG-1, (homologo de la familia de la MINDIN /F-espondina) fragmentos de anticuerpos, o miméticos de los anticuerpos conjugados con moléculas asociadas, tales como fármacos, radioisotopos y citotoxinas, donde la molécula asociada ejerce su efecto sin importar si el conjugado enlazado a RG-1 es interiorizado dentro de una célula diana, son utiles para tratar cánceres. Reivindicacion 1: Un conjugado de anticuerpo-molécula asociada que comprende un anticuerpo monoclonal humano o una porcion de enlace al antígeno del mismo conjugado con una molécula asociada, donde el anticuerpo o la porcion de enlace al antígeno del mismo se enlaza a RG-1 humano y el conjugado exhibe al menos una de las siguientes características: (a) se enlaza a RG-1 humano con una KD de 1 x 10-8 M o menor; (b) inhibe el crecimiento de las células que expresan RG-1 in vivo
ARP080105135A 2007-11-30 2008-11-26 Conjugados de anticuerpos anti- rg-1 AR069746A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99169007P 2007-11-30 2007-11-30

Publications (1)

Publication Number Publication Date
AR069746A1 true AR069746A1 (es) 2010-02-17

Family

ID=40427118

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080105135A AR069746A1 (es) 2007-11-30 2008-11-26 Conjugados de anticuerpos anti- rg-1

Country Status (18)

Country Link
US (1) US20110020329A1 (es)
EP (1) EP2211908A2 (es)
JP (1) JP2011505371A (es)
KR (1) KR20100101122A (es)
CN (1) CN101951960A (es)
AR (1) AR069746A1 (es)
AU (1) AU2008331507A1 (es)
BR (1) BRPI0819765A2 (es)
CA (1) CA2707443A1 (es)
CL (1) CL2008003525A1 (es)
CO (1) CO6210734A2 (es)
EA (1) EA201000921A1 (es)
IL (1) IL206060A0 (es)
MX (1) MX2010005683A (es)
NZ (1) NZ586514A (es)
TW (1) TW200930407A (es)
WO (1) WO2009073524A2 (es)
ZA (1) ZA201003729B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070042967A (ko) * 2004-07-16 2007-04-24 마이크로메트 에이지 발현 증강된 폴리펩티드
US8889868B2 (en) 2008-11-03 2014-11-18 Syntarga Bv CC-1065 analogs and their conjugates
CN106749665B (zh) 2010-04-21 2021-03-26 辛塔佳有限公司 Cc-1065类似物和双功能接头的缀合物
CA2800769C (en) * 2010-05-27 2021-11-02 Genmab A/S Monoclonal antibodies against her2 epitope
CA2800785C (en) 2010-05-27 2019-09-24 Genmab A/S Monoclonal antibodies against her2
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
LT3092010T (lt) 2014-01-10 2018-10-25 Synthon Biopharmaceuticals B.V. Metodas, skirtas gryninimui cys-sujungtų antikūno-vaisto konjugatų
WO2015113476A1 (zh) * 2014-01-29 2015-08-06 上海恒瑞医药有限公司 配体-细胞毒性药物偶联物、其制备方法及其应用
WO2019027935A1 (en) 2017-07-31 2019-02-07 Tizona Therapeutics ANTI-CD39 ANTIBODIES, COMPOSITIONS COMPRISING ANTI-CD39 ANTIBODIES AND METHODS OF USING ANTI-CD39 ANTIBODIES

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912227A (en) * 1984-02-21 1990-03-27 The Upjohn Company 1,2,8,8A-tetrahydrocyclopropa(c)pyrrolo(3,2-e)-indol-4-(5H)-ones and related compounds
US4978757A (en) * 1984-02-21 1990-12-18 The Upjohn Company 1,2,8,8a-tetrahydrocyclopropa (C) pyrrolo [3,2-e)]-indol-4(5H)-ones and related compounds
US5332837A (en) * 1986-12-19 1994-07-26 The Upjohn Company CC-1065 analogs
US5084468A (en) * 1988-08-11 1992-01-28 Kyowa Hakko Kogyo Co., Ltd. Dc-88a derivatives
JP2598116B2 (ja) * 1988-12-28 1997-04-09 協和醗酵工業株式会社 新規物質ｄｃ１１３
JP2510335B2 (ja) * 1989-07-03 1996-06-26 協和醗酵工業株式会社 Ｄｃ―８８ａ誘導体
US5187186A (en) * 1989-07-03 1993-02-16 Kyowa Hakko Kogyo Co., Ltd. Pyrroloindole derivatives
JPH05508394A (ja) * 1990-04-25 1993-11-25 ファルマシア・アンド・アップジョン・カンパニー 新規なｃｃ―１０６５アナログ
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
PT705833E (pt) * 1994-04-22 2004-11-30 Kyowa Hakko Kogyo Kk Derivado de dc-89
JPH07309761A (ja) * 1994-05-20 1995-11-28 Kyowa Hakko Kogyo Co Ltd デュオカルマイシン誘導体の安定化法
US5871969A (en) * 1996-02-12 1999-02-16 Human Genome Sciences, Inc. Nucleic acids encoding human neuronal attachment factor-1
US6682902B2 (en) * 1999-12-16 2004-01-27 Schering Aktiengesellschaft DNA encoding a novel RG1 polypeptide
US7129261B2 (en) * 2001-05-31 2006-10-31 Medarex, Inc. Cytotoxic agents
JP2005502703A (ja) * 2001-09-07 2005-01-27 ザ スクリプス リサーチ インスティテュート Ｃｃ−１０６５およびデュオカルマイシンのｃｂｉ類似体
US7091186B2 (en) * 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
JP4680902B2 (ja) * 2003-07-22 2011-05-11 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト Ｒｇ１抗体及びその使用
CA2564076C (en) * 2004-05-19 2014-02-18 Medarex, Inc. Chemical linkers and conjugates thereof
US7691962B2 (en) * 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
US7714016B2 (en) * 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
EA016577B1 (ru) * 2005-09-26 2012-06-29 Медарекс, Инк. Конъюгаты антитело-лекарство и их применение
WO2007059404A2 (en) * 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
WO2007137760A2 (en) * 2006-05-25 2007-12-06 Bayer Schering Pharma Aktiengesellschaft Dimeric molecular complexes

Also Published As

Publication number Publication date
US20110020329A1 (en) 2011-01-27
CA2707443A1 (en) 2009-06-11
WO2009073524A3 (en) 2009-12-10
EA201000921A1 (ru) 2010-12-30
WO2009073524A2 (en) 2009-06-11
NZ586514A (en) 2012-05-25
AU2008331507A1 (en) 2009-06-11
MX2010005683A (es) 2010-06-11
CN101951960A (zh) 2011-01-19
ZA201003729B (en) 2011-08-31
BRPI0819765A2 (pt) 2015-05-05
EP2211908A2 (en) 2010-08-04
KR20100101122A (ko) 2010-09-16
JP2011505371A (ja) 2011-02-24
CL2008003525A1 (es) 2010-01-22
IL206060A0 (en) 2010-11-30
CO6210734A2 (es) 2010-10-20
TW200930407A (en) 2009-07-16

Similar Documents

Publication Publication Date Title
AR069746A1 (es) Conjugados de anticuerpos anti- rg-1
AR069747A1 (es) Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion
BR112012023010A2 (pt) "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37"
WO2010009124A3 (en) Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
EA201270654A1 (ru) Моноклональные антитела, связывающие b7h6, и их применение
AR064360A1 (es) Anticuerpos humanos que se enlazan a cd70 y usos de los mismos
NI201000021A (es) Anticuerpos humanos de alta afinidad de factor de crecimiento de nervio humano.
EA201990781A9 (ru) Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение
CY1121536T1 (el) Ανθρωπινα αντισωματα εναντι-αλφα-συνουκλεϊνης
ES2674567T3 (es) Proteínas de fusión biespecíficas
AR069903A1 (es) Conjugado anticuerpo- molecula asociada dirigidos a la proteina tirosina quinasa 7 (ptk 7), composicion farmaceutica que lo comprende, acido nucleico, factor de expresion y celula huesped relacionados y su uso para preparar un medicamento util para el tratamiento o prevencion de cancer
CY1119591T1 (el) Πρωτεϊνες ειδικης συνδεσης και χρησεις αυτων
MX2010001757A (es) Anticuerpo monoclonal 175 que activa el receptor egf y derivados y usos del mismo.
WO2019215510A8 (en) Compositions and methods related to anti-cd19 antibody drug conjugates
WO2008091911A3 (en) Use of antibody conjugates
MY150246A (en) Alpha 5 - beta 1 antibodies and their uses
CY1114953T1 (el) Αντι-βητα-αμυλοειδους αντισωμα και χρησεις αυτου
BR112018008983A2 (pt) moléculas de ligação específicas para asct2 e seus usos
IL319612A (en) Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
BR112012014984A2 (pt) anticorpos dirigidos contra o receptor da transferrina e as suas utilizacoes para a imunoterapia dos tumores que dependem do ferro
ES2639026T3 (es) Anticuerpos totalmente humanos específicos para CADM1
UA99602C2 (ru) Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток
CY1117355T1 (el) Μονοκλωνικα αντισωματα αντi-φερροπορτiνης 1 και χρησεις αυτων
ATE288960T1 (de) Humanisierte monoklonale antikörper mit hoher affinität gegen tag-72
PE20090426A1 (es) Composicion vacunal homogenea para el tratamiento del cancer y su metodo de obtencion

Legal Events

Date Code Title Description
FA Abandonment or withdrawal